8.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
8.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
8.2 North America Biologics Market - Opportunity Analysis Index,
By Product Type,
By Therapeutic Area,
By Manufacturing Process,
and Region, 2024 - 2031
9. North America North America Biologics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
9.1 By Product Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
9.1.1 Monoclonal Antibodies
9.1.2 Vaccines
9.1.3 Recombinant Proteins
9.1.4 Cell Therapy
9.1.5 Gene Therapy
9.2 By Therapeutic Area Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
9.2.1 Oncology
9.2.2 Autoimmune Diseases
9.2.3 Infectious Diseases
9.2.4 Cardiovascular Diseases
9.2.5 Neurology
9.2.6 Others
9.3 By Manufacturing Process Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
9.3.1 Outsourced
9.3.2 In-House
9.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
9.4.1 United States
9.4.2 Canada
9.5 North America
North America Biologics Market – Opportunity Analysis Index,
By Product Type,
By Therapeutic Area,
By Manufacturing Process,
and Country, 2024 - 2031
9.6 Regional Trends Analysis
9.7 North America North America Biologics Market Research Report - Company Profiles
9.7.1 Company 1 (United States)
9.7.2 Company 2 (Canada)
9.7.3 Company 3 (Canada)
10. Competition Landscape
10.1 Strategic Dashboard of Top Market Players
10.2 Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis)
10.2.1 Roche Holding AG
10.2.2 Pfizer Inc.
10.2.3 Johnson & Johnson
10.2.4 Amgen Inc.
10.2.5 AbbVie Inc.
11. Data Collection Method and Research Approach 12. Principal Presumptions and Acronyms
Methodology & Credibility
Built for enterprise decisions, not vanity metrics.
Triangulated Sizing
Bottom-up, top-down, and peer benchmarks reconciled by analysts.
Primary + Secondary Research
Executive interviews combined with validated public and paid sources.
Scenario & Sensitivity
Base, bull and bear cases to stress-test strategic moves.
Need Confidence Fast?
We’ll map your questions to the report in 15 minutes.